In patients with pharyngeal cancer, intensity-modulated proton therapy (IMPT) with a model-based approach was associated with a lower rate of acute toxicities, especially dysphagia, compared with those receiving intensity-modulated X-ray therapy (IMXT), according to results of a retrospective analysis now published in the Journal of Radiation Research. "Radiation therapy is the mainstay treatment for head and neck cancer," write the investigators, led by Koichi Yasuda, MD, PhD, Assistant Profess...
In patients with locally advanced non-small cell lung cancer (NSCLC) treated with thoracic radiotherapy, a greater left anterior descending (LAD) coronary artery dose exposure was associated with an increased risk of major adverse cardiac events (MACE) and all-cause mortality, particularly in patients with baseline coronary heart disease (CHD), according to results of a cohort study now published in JAMA Oncology. "Development of cardiac adverse events is a well-recognized risk following radioth...
The FDA recently approved new doses of durvalumab (Imfinzi®, AstraZeneca) for the treatment of patients with previously treated advanced urothelial carcinoma and unresectable stage III non-small cell lung cancer. "Durvalumab, a selective, high-affinity, engineered human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80, is approved in the US, Japan, and several other countries for the treatment of patients with unresectable, stage III NSCLC whose disease has not progressed following conc...
In patients who have been diagnosed with T1 N0 M0 triple-negative breast cancer (TNBC), age plays a role in whether chemotherapy or radiotherapy will lead to better outcomes for overall survival and breast cancer–specific survival (BCSS), according to the results of a cohort study now published in JAMA Network Open. The investigators, led by Zhen Zhai, MD, of the Department of Breast Surgery in the First Affiliated Hospital in the College of Medicine at Zhejiang University in Hangzhou, China, en...
Fifteen-year results of a randomized phase 3 trial show that for patients with stage I–III breast cancer, internal mammary and medial supraclavicular (IM-MS) lymph node chain irradiation reduces breast cancer mortality and breast cancer recurrence but does not produce a significant improvement in overall survival. "Ten-year results from several studies showed improved disease-free survival and distant metastasis-free survival, reduced breast cancer-related mortality, and variable effects on over...